Posted by Michael Wonder on 08 Apr 2021
Immutep achieves fast track designation from US FDA for EFTI, a soluble LAG-3 protein, in first-line recurrent/metastatic head & neck cancer
8 April 2021 - Fast track was granted based on the promising data package from Immutep, including from Immutep’s Phase 2 TACTI-002 trial (KEYNOTE-798) in head and neck squamous cell carcinoma.
Immutep has received fast Track designation in first-line recurrent or metastatic head and neck squmaous cell carcinoma from the United States FDA.
